Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models
Acta Biomaterialia · 2024
DOI: 10.1016/j.actbio.2024.05.045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2024. Verfasst von Qilong Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, 130061, PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Nanomedicine. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: First Hospital of Jilin University, Natural Science Foundation of Jilin Province.
Abstract (Originalsprache)
Advanced hepatocellular carcinoma (HCC) is one of the most challenging cancers because of its heterogeneous and aggressive nature, precluding the use of curative treatments. Sorafenib (SOR) is the first approved molecular targeting agent against the mitogen-activated protein kinase (MAPK) pathway for the noncurative therapy of advanced HCC; yet, any clinically meaningful benefits from the treatment remain modest, and are accompanied by significant side effects. Here, we hypothesized that using a nanomedicine platform to co-deliver SOR with another molecular targeting drug, metformin (MET), could tackle these issues. A micelle self-assembled with amphiphilic polypeptide methoxy poly(ethylene glycol)-block-poly(L-phenylalanine-co-l-glutamic acid) (mPEG-b-P(LP-co-LG)) (PM) was therefore designed for combinational delivery of two molecular targeted drugs, SOR and MET, to hepatomas. Compared with free drugs, the proposed, dual drug-loaded micelle (PM/SOR+MET) enhanced the drugs' half-life in the bloodstream and drug accumulation at the tumor site, thereby inhibiting tumor growth effectively in the preclinical subcutaneous, orthotopic and patient-derived xenograft hepatoma models without causing significant systemic and organ toxicity. Collectively, these findings demonstrate an effective dual-targeting nanomedicine strategy for treating advanced HCC, which may have a translational potential for cancer therapeutics. STATEMENT OF SIGNIFICANCE: Treatment of advanced hepatocellular carcinoma (HCC) remains a formidable challenge due to its aggressive nature and the limitations inherent to current therapies. Despite advancements in molecular targeted therapies, such as Sorafenib (SOR), their modest clinical benefits coupled with significant adverse effects underscore the urgent need for more efficacious and less toxic treatment modalities. Our research presents a new nanomedicine platform that synergistically combines SOR with metformin within a specialized diblock polypeptide micelle, aiming to enhance therapeutic efficacy while reducing systemic toxicity. This innovative approach not only exhibits marked antitumor efficacy across multiple HCC models but also significantly reduces the toxicity associated with current treatments. Our dual-molecular targeting approach unveils a promising nanomedicine strategy for the molecular treatment of advanced HCC, potentially offering more effective and safer treatment alternatives with significant translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Vascular Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, 130061, PR China.
- Department of Immunology and Pathogenic Biology, College of Medicine, Yanbian University, Yanji, 133002, PR China.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, 130061, PR China. Electronic address: z_ping@jlu.edu.cn.
- Department of Vascular Surgery, General Surgery Center, the First Hospital of Jilin University, Changchun, 130061, PR China. Electronic address: chengzh@jlu.edu.cn.
Förderung
- First Hospital of Jilin University
- Natural Science Foundation of Jilin Province
Zitieren
APA
Wang, Q., Sun, X., Fang, X., Wang, Z., Wang, H., Sun, S., Wang, S., Li, T., Zhang, P., & Cheng, Z. (2024). Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2024.05.045
Vancouver
Wang Q, Sun X, Fang X, Wang Z, Wang H, Sun S, et al. Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models. Acta Biomaterialia. 2024. doi:10.1016/j.actbio.2024.05.045
BibTeX
@article{Wang2024,
author = {Wang, Qilong and Sun, Xiwei and Fang, Xizhu and Wang, Zhongying and Wang, Haodong and Sun, Siqiao and Wang, Shuai and Li, Tingting and Zhang, Ping and Cheng, Zhihua},
title = {Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models},
journal = {Acta Biomaterialia},
year = {2024},
doi = {10.1016/j.actbio.2024.05.045}
}
EUVIMED